Pharmaceutical research has been bogged down by exceptionally high costs and extended clinical trials that are becoming less and less effective. It appears this industry is ripe for adopting open practices in the development process, and many executives and researchers are looking for ways to make drug research more transparent while protecting the interests of pharmaceutical companies.
